207 Perry Parkway
21 articles with GeneDx
Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it has completed the acquisition of GeneDx, LLC (“GeneDx”), a leader in genomic testing and analysis for rare disorders, from OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”).
Study of More Than 18,000 Patients Finds Exome Sequencing Delivers Higher Diagnostic Rates for Autism Spectrum Disorders
GeneDx, LLC, a leader in genomic analysis, unveiled new data demonstrating positive outcomes of exome analysis for individuals with autism spectrum disorders, supporting the use of a broader genetic testing approach to diagnose ASD.
What if infants with genetic illnesses could be diagnosed in a matter of days? New research surrounding rapid whole genome sequencing suggests that soon, they could be.
GeneDx, LLC, a leader in genomic analysis, today announced new research in collaboration with the University of Washington, Seattle Children's and the Brotman-Baty Institute during the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting to diagnose critically ill infants in the neonatal intensive care unit.
GeneDx, Inc., today announced newly published research demonstrating the value of data sharing and research participation on a platform that supports clinician connections to rapidly uncover new gene-disease relationships, an approach which has resulted in publication of more than 200 new associations.
Saol Therapeutics, a company researching new treatments for rare diseases, is pleased to announce a collaboration with GeneDx, Inc. a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company, to assist in identifying patients diagnosed with a rare mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency who may be eligible to participate in a Phase 3 clinical trial.
Pfizer's Clostridioides difficile infection vaccine failed to hit the mark, BMS announced priority review for Opdivo in resectable Non-Small Cell Lung Cancer, and Saol enlists help from GeneDx.
Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
Sema4, an AI-driven genomic and clinical data intelligence platform company, and OPKO Health, Inc., a multinational biopharmaceutical and diagnostics company, announced they have signed a definitive agreement for Sema4 to acquire OPKO’s wholly owned subsidiary, GeneDx, Inc., a leader in genomic testing and analysis, from OPKO.
Taysha Gene Therapies Announces Sponsored Genetic Testing for Giant Axonal Neuropathy (GAN) in Partnership with GeneDx as well as a Collaboration with Hereditary Neuropathy Foundation and Charcot-Marie-Tooth Association Centers of Excellence
Taysha Gene Therapies, Inc. today announced sponsored genetic testing for giant axonal neuropathy (GAN) in partnership with GeneDx, Inc.
Krystal Biotech and GeneDx Announce Collaboration to Provide No-charge Genetic Testing for Patients with Suspected Dystrophic Epidermolysis Bullosa (DEB)
Krystal Biotech, Inc. today announced a collaboration offering no-charge genetic testing for all types of Epidermolysis Bullosa (EB).
GeneDx, Inc., a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company, announced it has completed clinical genetic exome sequencing for more than 300,000 patients, making the company's dataset the largest of its kind in the world.
OPKO Health, Inc. announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO’s BioReference Laboratories.
OPKO Health's GeneDx Adds Repeat Expansion Analysis Genetic Tests for Diagnosis of Spinocerebellar Ataxia (SCA), Friedreich Ataxia, and Other Common Forms of Hereditary Ataxia
GeneDx, Inc., a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today launched several new genetic tests, including repeat expansion analysis for spinocerebellar ataxia (SCA), Friedreich ataxia, and other common forms of hereditary ataxias.
OPKO Health's GeneDx Enters into Agreement with Pediatrix Medical Group to Offer Neonatal Genomic Services
GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), the global leader in neonatal and pediatric genetic testing, announced the entrance into an agreement with Pediatrix Medical Group ("Pediatrix"), the nation's leading provider of maternal-fetal, and pediatric medical and surgical sub
GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc., an OPKO Health company, announced the launch of GenomeXpress, a rapid genome sequencing test.
Opko Health's GeneDx Recognizes International Rare Disease Day With Donation Of Free Exome Tests To Syndromes Without A Name
GeneDx And Its Parent BioReference Laboratories, Inc. Announce Settlement Of Their Cancer Gene Testing Patent Dispute With Myriad Genetics, Inc.
GeneDx Growing Array CGH Testing Volumes To 100,000 Tests A Year; Relies On Cartagenia n.v. Bench Lab CNV Platform For Automated Variant Assessment And Reporting